2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD28

CD28

CD28, a cell surface glycoprotein receptor, predominantly expressed on activated T cells, belongs to the Ig superfamily and provides a critical co-stimulatory signal. Its ligands, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. CD28 interacts with the CD80 dimer with relatively high affinity and the CD86 monomer with lower affinity, mediating T cell co-stimulation in conjunction with T cell receptor (TCR) signals. CD28 drives critical intracellular biochemical events including unique phosphorylation and transcriptional signaling, metabolism, and the production of key cytokines, chemokines, and survival signals that are essential for long-term expansion and differentiation of T cells. Most importantly, treatment of mice with a soluble CD28 antagonist induced antigen-specific tolerance that prevented the progression of autoimmune diseases and organ graft rejection.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9975
    Theralizumab
    		Agonist
    Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis.
    Theralizumab
  • HY-P99302
    Lulizumab
    		Inhibitor
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling.
    Lulizumab
  • HY-P99123
    Anti-Mouse CD28 Antibody (37.51)
    Anti-Mouse CD28 Antibody is an anti-mouse CD28 IgG antibody inhibitor derived from the host Syrian Hamster.
    Anti-Mouse CD28 Antibody (37.51)
  • HY-102090
    B7/CD28 interaction inhibitor 1
    		99.47%
    B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM.
    B7/CD28 interaction inhibitor 1
  • HY-P99961
    Tifcemalimab
    		Inhibitor
    Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer.
    Tifcemalimab
  • HY-P990752
    Nezastomig
    Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Nezastomig
  • HY-162810
    ICOS-IN-1
    ICOS-IN-1 (compound 9) is an inhibitor of the interaction between ICOS and ICOS-L (IC50=29.38 μM) and has activity in recognizing immune checkpoints.
    ICOS-IN-1
  • HY-P991038
    Zadoprubart
    HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Zadoprubart
  • HY-P99420
    Acazicolcept
    		Antagonist 99.27%
    Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities.
    Acazicolcept
  • HY-P99293
    Galiximab
    		Inhibitor 99.23%
    Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma.
    Galiximab
  • HY-P1698B
    Reltecimod TFA
    		Chemical 99.78%
    Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs).
    Reltecimod TFA
  • HY-P1698
    Reltecimod
    		Antagonist 99.88%
    Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs).
    Reltecimod
  • HY-100891
    CD80-IN-3
    		98.08%
    CD80-IN-3, a potent CD80 inhibitor, inhibits CD80/CD28 interaction with an EC50 of 630 nM and a Kd of 125 nM.
    CD80-IN-3
  • HY-N10445
    Maydispenoid A
    Maydispenoid A is a potent immunosuppressor. Maydispenoid A can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation.
    Maydispenoid A
  • HY-N10446
    Maydispenoid B
    Maydispenoid B is a potent immunosuppressor. Maydispenoid B can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation.
    Maydispenoid B
  • HY-P990938
    Pegrizeprument
    HY-P990938 is an CD28-targeting Fab'-G1 -κ type chimeric antibody.
    Pegrizeprument
Cat. No. Product Name / Synonyms Application Reactivity